FDA-cleared profile

Saige-Dx

DeepHealth, Inc. · Mammography/DBT · FDA-cleared (510(k))

Concurrent-reading software for screening DBT mammography that highlights suspected soft-tissue lesions and calcifications for physician review.

Clinical role
Concurrent adjunctive reading aid; it does not replace physician review or clinical judgment, and decisions must not be made solely from its analysis.
Images and patients
Mammography/DBT · Breast; screening DBT findings and calcifications
Key limitation
Use is limited to the labeled screening population and compatible DBT hardware; it is not a substitute for full physician review.

Overview status: Source-reviewed overview

Report a correction

Evaluation pilot

Before you shortlist

Exact FDA record: K220105 · Agent source review · . This is not clinician review or local acceptance.

Within this record's scope

  • Consider for concurrent screening DBT review in women aged 35 or older, using the labeled DBT stack and accompanying 2D images.

Limits to check

  • Full physician review remains required. This 2022 submission does not establish the current commercial release or support for another input configuration.

Questions for the vendor and your team

  1. Which installed version and licensed functions match the quoted Saige-Dx release, and what is its exact regulatory record?
  2. How will readers evaluate finding marks, suspicion levels and false findings on the department's representative screening workflow?

These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.

Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Image interpretation · source-reviewed 2026-11-09

Agent source review of original FDA labeling; not clinician sign-off or local workflow qualification.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?It analyzes a single screening DBT study, localizes suspected soft-tissue lesions and calcifications, and provides finding- and case-level suspicion information for physician review.
  • Which examinations and patients are in scope?It is intended for women aged 35 years or older undergoing screening mammography with compatible DBT hardware, using DBT stacks with accompanying full-field digital mammography and/or synthetic 2D images.
  • Who uses it?Interpreting physicians qualified to read screening mammography examinations use the output during concurrent review.
  • What does the software produce?It produces finding-level boxes and suspicion levels, an aggregate case suspicion level, a DICOM Structured Report for workstation overlay, and a DICOM Secondary Capture summary report.
  • What is its most important limitation?It is an adjunct, not a replacement for full physician review or clinical judgment, and decisions must not be made solely from its analysis.

Clinical takeaway. Saige-Dx is a concurrent-reading aid for screening DBT mammography. Its marks and suspicion information support, but do not replace, physician interpretation.

Evidence takeaway. The FDA submission describes separate reader and standalone studies. In the 240-case reader study, aided reader AUC was 0.925 versus 0.865 unaided; this reader-aided result is not a standalone sensitivity or specificity measure.

Additional limitations
  • The exact-submission materials do not establish a current commercial version, local compatibility, or site-specific workflow configuration.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K220105 · agent source review 2026-11-09 · exact submission

Existing study anchor: Saige-DX regulatory performance study summary. Tested version label: Exact product version not reported; regulatory study summarized for FDA submission K220105.

What was tested?

Two different retrospective tests: a 240-case, 18-reader aided-versus-unaided MRMC study and a 1,304-case standalone test.

Source section: 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

On which cases and versions?

Reader cases used Hologic DBT, women 35 or older, 100 cancer and 140 non-cancer. The standalone set came from nine US sites with 136 cancer and 1,168 non-cancer. Do not add these into a single study sample.

Source section: 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

What changed?

The FDA summary reports increased reader ROC area with assistance. The reported reader-specificity difference has a confidence interval spanning zero, so a specificity improvement is not established. Standalone results remain separate from reader effects.

Source section: 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

What does this not establish?

Reader sensitivity changes are not standalone sensitivity, and previously withdrawn metrics remain withdrawn. The study does not establish reduced recalls, less rework, patient outcomes, performance on all vendors or local throughput.

Source section: 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

Study design, population and missing context
evidence Role
Retrospective MRMC reader study and separate retrospective standalone evaluation.

reader study · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

design
Reader study: 18 radiologists read 240 cases twice, aided and unaided, with at least four weeks washout. Standalone: blinded multicenter retrospective study of 1,304 cases.

reader study · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Training used six datasets from US and UK locations. Validation data came from different sites and did not overlap training.

training · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

evaluation Population
Reader set: 240 women age 35 or older, 100 cancer and 140 non-cancer. Standalone set: 1,304 cases, 136 cancer and 1,168 non-cancer. The sets are not combined into one denominator.

reader study · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

reference Standard
Pathology and expert reference review; two breast-imaging specialists and a third adjudicator for disagreements in the reader-study truthing process.

reader study · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

comparator
Reader interpretation with versus without Saige-Dx. Standalone performance is a separate endpoint, not the aided-reader effect.

reader study · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

sites
The standalone study used nine US clinical sites. Reader-study site count is not provided in the reviewed text.

validation · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

scanner Protocol
Reader cases were Hologic DBT with accompanying 2D mammograms. Do not extend the study result to every DBT manufacturer.

reader study · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

sample Composition
Reader cases: 100/240 cancer, including 67 cancers recalled and 33 not recalled in routine practice; 140/240 non-cancer. Standalone: 136/1,304 cancer and 1,168/1,304 non-cancer.

reader study · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

sponsor Involvement
DeepHealth describes the training/test separation and submitted the manufacturer regulatory study package. Investigator independence is not established by data separation.

regulatory summary · 510(k) summary, section 7: Performance Data, Reader Study and Standalone Study

Public-label constraints

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Exact FDA submission K220105 · agent source review 2026-11-09 · Saige-Dx

Authorized population

Women 35 years of age or older undergoing screening mammography.

Label age limits

Women 35 years of age or older. No numerical upper bound transcribed.

Documented care setting

Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.

Modality and protocol

DBT image stacks and accompanying 2D images, including FFDM and/or synthetic images, from screening mammograms with compatible DBT hardware.

Acquisition constraints

Compatible DBT hardware; a single DBT study supplies DICOM DBT stacks and associated 2D images.

Exclusions and human review

Adjunct tool, not a replacement for a physician's own mammogram review. Decisions should not be made solely based on Saige-Dx.

Purpose
Concurrent reading aid for interpreting physicians on screening mammograms with compatible DBT hardware; it analyzes DBT stacks and accompanying full-field digital or synthetic 2D images to identify soft-tissue lesions and calcifications that may indicate cancer and assigns finding- and case-level suspicion levels.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Concurrent adjunctive reading aid; it does not replace physician review or clinical judgment, and decisions must not be made solely from its analysis.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DICOM x-ray mammogram files from a single DBT study, including DBT image stacks and accompanying full-field digital mammography and/or synthetic 2D images.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Finding-level bounding boxes and Finding Suspicion Levels, an aggregate Case Suspicion Level, a DICOM Structured Report with markings for workstation overlay, and a DICOM Secondary Capture summary report.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Screening mammography for women aged 35 years or older using compatible DBT hardware.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Interpreting physicians qualified to read screening mammography examinations.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The FDA labels Saige-Dx as an adjunct and not a replacement for full physician review; the patient population is women aged 35 or older undergoing screening. Reader-study and standalone results are separate, and the packet does not establish current commercial version or local compatibility.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
The balanced MRMC reader study included 18 MQSA-qualified radiologists reading 240 cases twice, with 100 pathology-proven cancers and 140 confirmed non-cancers, using two expert truthers and adjudication when needed. Reader AUC was 0.865 unaided versus 0.925 aided (difference 0.06, 95% CI 0.041-0.079, p<0.00001); average reader sensitivity increased by 8.8% (95% CI 7.0%-10.6%) and specificity by 0.9% (95% CI -0.9% to 2.7%). A separate standalone study used 1,304 cases from nine U.S. sites and reported AUC 0.930 (95% CI 0.902-0.958). Reader deltas and AUC are not standalone sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The balanced MRMC reader study included 18 MQSA-qualified radiologists reading 240 cases twice, with 100 pathology-proven cancers and 140 confirmed non-cancers, using two expert truthers and adjudication when needed. Reader AUC was 0.865 unaided versus 0.925 aided (difference 0.06, 95% CI 0.041-0.079, p<0.00001); average reader sensitivity increased by 8.8% (95% CI 7.0%-10.6%) and specificity by 0.9% (95% CI -0.9% to 2.7%). A separate standalone study used 1,304 cases from nine U.S. sites and reported AUC 0.930 (95% CI 0.902-0.958). Reader deltas and AUC are not standalone sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Value withdrawn pending re-verification
  • Corrected record
  • Exact FDA submission
  • Checked 2026-09-12

Previous value withdrawn: The old value is a change in reader sensitivity, not standalone sensitivity.

Reported specificity
Value withdrawn pending re-verification
  • Corrected record
  • Exact FDA submission
  • Checked 2026-09-12

Previous value withdrawn: The old value is the upper confidence bound for the reader-sensitivity change, not standalone specificity.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Saige-DX regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K220105
  • Samplen=1304
  • Sites9
  • IndependenceIndependence not established

K220105

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K220105. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM x-ray mammogram files from a single DBT study, including DBT image stacks and accompanying full-field digital mammography and/or synthetic 2D images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K220105: Saige-Dx

  2. Routing

    Source context, not route validation: DICOM Structured Report and Secondary Capture outputs are intended for overlay and review on a viewing workstation with compatible DBT hardware; the packet does not establish specific PACS, RIS, EHR, or interface versions.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K220105: Saige-Dx

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-11-12 does not establish this claim; it states no deployment or hosting model.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-12 ·

  4. Returned objects

    Source context, not route validation: Finding-level bounding boxes and Finding Suspicion Levels, an aggregate Case Suspicion Level, a DICOM Structured Report with markings for workstation overlay, and a DICOM Secondary Capture summary report.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K220105: Saige-Dx

  5. Viewer/worklist/report

    Unresolved route: Finding-level bounding boxes and Finding Suspicion Levels, an aggregate Case Suspicion Level, a DICOM Structured Report with markings for workstation overlay, and a DICOM Secondary Capture summary report.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K220105: Saige-Dx

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
DICOM Structured Report and Secondary Capture outputs are intended for overlay and review on a viewing workstation with compatible DBT hardware; the packet does not establish specific PACS, RIS, EHR, or interface versions.
  • Exact FDA submission
  • Checked 2026-09-09

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

workstation is explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Saige-Dx; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220105
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Breast; screening DBT findings and calcifications
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-05-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-09Last searched
25Fields reviewed
9Source classes checked
1Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR provides bounded exact-submission catalog context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 1 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K220105 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Withdrawn - checked 2026-11-12 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-11-12 does not establish this claim; it states no deployment or hosting model.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K220105: Saige-Dx

    U.S. Food and Drug Administration - Published 2022-05-12 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Saige-DX model card (K220105)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K220105

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K220105 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K254131

BAC

DeepHealth, Inc.

Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.

Modality
Mammography/DBT
Anatomy
Breast; breast arterial calcifications
Decision
2026-05-21
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history